Globus Medical, Inc. (GMED)
NYSE · Healthcare · Medical Devices
$76.57+1.28%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $10.3B
- P/E (trailing)
- 19.6
- Forward P/E
- 14.2
- 52-week range
- $56.50 – $101.40
- 52-week change
- +27.47%
- EPS (trailing)
- $3.90
- Analyst rating
- 1.9 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $2.9B (+16.65%)
- Net income
- $538M
- Operating margin
- 16.3%
- Diluted EPS
- $3.92
- Free cash flow
- $589M
From the company’s annual report on SEC EDGAR.
About Globus Medical, Inc.
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems.
Headquarters: Audubon, United States · 6,000 employees · globusmedical.com